drugset / Trial / NCT06889350

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

NCT06889350

Phase 1 Completed 40 enrolled Handok Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Timeline

Start
2025-03-26
Primary completion
2025-04-13
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule Oral
Subject HD-P023 Unknown Oral
Comparator Teneligliptin Small molecule Oral

Indications

No indication recorded.